Genzyme's Pipeline Outlook

	Research	Preclinical	Phase 1	Phase 2	Phase 3	Postmarketing Studies
GENETIC DISEASE
Cerezyme product enhancements
Fabrazyme multiple studies
Myozyme late-onset Pompe disease
Genz-112638 small molecule Gaucher disease
Acid sphingomyelinase type B Niemann-Pick disease
Gene therapy Pompe disease
RENAL DISEASE
Renvela chronic kidney disease
Renvela chronic kidney disease on dialysis
Renvela powder formulation
GC1008 kidney sclerosis
Small molecule polycystic kidney disease
SPECIALTY PRODUCTS
Thyrogen ablation of thyroid cancer
Tolevamer (toxinbinder) C. difficile-associated disease
TSH nontoxic multinodular goiter
Gene therapy Parkinson's disease
Gene therapy age-related macular degeneration
Gene Therapy ALS
TRANSPLANT AND IMMUNE DISEASE
Mozobil stem cell mobilization
Alemtuzumab multiple sclerosis
Thymoglobulin living kidney donor
Thymoglobulin liver transplant
FC receptor 3 antagonist idiopathic thrombocytopenic purpura
GC1008 pulmonary fibrosis
Thymoglobulin type 1 diabetes
Genz-642347 type 2 diabetes
Campath immune-mediated diseases
Genz - 29155 solid organ transplant
ONCOLOGY
Campath chronic lymphocytic leukemia
Clolar pediatric acute lymphocytic leukemia
Clofarabine adult acute myeloid leukemia
GC1008 solid tumors
Clofarabine myelodysplastic syndromes
Tasidotin solid tumors
Clofarabine solid tumors
Topoisomerase I Inhibitors solid tumors
CARDIOVASCULAR DISEASE
Cholestagel LDL-C reduction
Gene therapy peripheral arterial disease
Adult stem cells heart failure
ORTHOPAEDICS AND BIOSURGICAL SPECIALTIES
Second generation Synvisc
Hylastan new formulation
Sepraspray new formulation adhesion barrier
Third generation cartilage repair
Third generation viscosupplement